Pamplona Capital is seeking a buyer for Calyx, the clinical trial tech and medical imaging arm that spun out from Parexel before its $8.5 billion buyout last year, multiple sources tell Axios.
Why it matters: Calyx sits smack in the middle of a hot sector experiencing strong tailwinds and commanding tons of private equity interest.
